Sign In
Last checked at 
29 May 2026 07:00
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
Director/PDMR Shareholding
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitute, announces that the Company has been informed that David Blain, a Director of the Company, made the following purchase of ordinary shares in the capital of the Company.
Further details are set out in the Notification of Dealing Form below.
Director | Purchase price | Ordinary shares purchased | Resultant interest in ordinary shares | Resultant percentage of issued ordinary shares |
David Blain | 6.17 pence | 158,965 | 243,018 | 0.24% |
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact: OptiBiotix Health plc | www.optibiotix.com | |
Neil Davidson, Chairman |
| |
Stephen O'Hara, Chief Executive | ||
| ||
Cairn Financial Advisers LLP (NOMAD and Broker) | Tel: 020 7213 0880 | |
Liam Murray / Ludovico Lazzaretti / James Western
| ||
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | David Blain | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Finance Director | |||||
b. | Initial notification/ Amendment | Initial Notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | OptiBiotix Health Plc | |||||
b. | LEI | 213800UKYQFT941QHS14 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 2p each
ISIN: GB00BP0RTP38 | |||||
b. | Nature of the transaction | Purchase of ordinary shares
| |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
6.17 pence | 158,965 | ||||||
d. | Aggregated information - Volume - Price |
See above | |||||
e. | Date of the transaction | 28 May 2026 | |||||
f. | Place of the transaction | London Alternative Market (AIMX) | |||||
Follow the stocks
